GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2007

Antipsychotic from Otsuka and Bristol-Myers Squibb Wins Label Expansion

  • Otsuka Pharmaceutical and Bristol-Myers Squibb received FDA approval for Abilify® to treat schizophrenia in adolescents between 13 and 17 years. This atypical antipsychotic is reportedly the only available dopamine partial agonist. The drug treats the positive and negative symptoms of the disease, according to the companies.

    Otsuka Pharmaceutical discovered Abilify. Along with Bristol-Myers Squibb, the firm has commercializes the drug in the U.S. and major European countries. In November 2002, Abilify was indicated as a schizophrenia therapy in adults.

    In November 2002, Abilify was indicated as a schizophrenia therapy in adults. It is also used to treat acute manic or mixed episodes associated with bipolar I disorder in adults.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »